Home > Press > US Navy Begins Use of Industrial Nanotech Patented Product for Lead Abatement
Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology, announced today the use of the Company's nanotechnology based coating on US Navy buildings for lead abatement. Nansulate LDX is the Company's patented innovative lead encapsulation coating and is being applied at a Pacific US Navy facility by a military contractor for encapsulation of the existing lead-based paint.
US Navy Begins Use of Industrial Nanotech Patented Product for Lead Abatement
NAPLES, FL | Posted on July 24th, 2007
"This is a relatively small initial order, but it is a very significant breakthrough in our ongoing efforts to gain market share for Nansulate LDX throughout US Government facilities worldwide. The performance capabilities of our new environmentally safe, water based, lead abatement coating offers a new technology in lead abatement that can be applied to any substrate, forming a barrier coat to seal highly toxic lead paints," explained Francesca Crolley VP of Operations for Industrial Nanotech. "In addition to superior performance compared to traditional lead encasement coatings, Nansulate LDX offers the additional benefits which are the standard of Nansulate product line; the combination of thermal insulation, protection against corrosion, and the prevention of mold growth without the use of toxic moldicides. The ease of application, the performance criteria, and surface tolerance make Nansulate LDX a premier lead abatement coating."
Other facilities have recently utilized Nansulate LDX for superior lead encapsulation. The application of Nansulate LDX to a commercial office project by Southern Environmental Services in Marietta, Georgia was successfully completed. The 30,000 square-foot building was previously contaminated with lead. The product also offers an eco-friendly alternative for environmental remediation.
The dangers of lead-based paint have become the object of multiple state and federal mandatory health regulations. Approximately 75% of homes built prior to 1978 contain lead-based paint. According to a U.S. Environmental Protection Agency (EPA) estimate, lead abatement costs for residential units nationwide are approximately $570 billion, with another $500 billion estimated for the cleanup of commercial facilities. Within the past fifteen years, encapsulation as an abatement technique has surfaced and has become a cost-effective alternative solution, typically costing between 50 to 80% less than the cost of lead paint removal and replacement.
About Industrial Nanotech, Inc.
Industrial Nanotech Inc. is quickly emerging as a global nanoscience solutions and research leader. The Company develops and commercializes new and innovative applications for nanotechnology. Additional information about the Company and its products can be found at their websites, ( http://www.industrial-nanotech.com ) and ( http://www.nansulate.com ).
Nansulate(R) is the Company's patented product line of specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, and resistance to mold growth in an environmentally safe, water-based, coating formulation. The Nansulate(R) Product Line includes both industrial and residential coatings.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
For more information, please click here
For Industrial Nanotech, Inc., Naples
Martin E. Janis & Company, Inc.
Beverly Jedynak, President, 312-943-1100 ext. 12
Martin E. Janis & Company, Inc.
Laura Grock, Vice President, 312-943-1100 ext. 13
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014
Nanomaterial Outsmarts Ions April 22nd, 2014
Thinnest feasible membrane produced April 17th, 2014
INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014
Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014
NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014
Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014
High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014
Industrial Nanotech, Inc. Lands First Major Order from Pemex, Mexico’s State-Owned Oil and Gas Company April 14th, 2014
TED Selects Nanotech for Branding and Security on 30th Anniversary Conferences: Nanotech and TED collaborate to create a custom security feature using nano-imaging March 17th, 2014
Simon Fraser University Completes Installation of Electron Microscopes from FEI: SFU’s new multi-million-dollar Centre for Soft Materials now offers the most advanced suite of microscopes in Western Canada March 11th, 2014
Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520 March 3rd, 2014